Serum neutrophil gelatinase-associated lipocalin and decreased kidney function as predictor of mortality and major adverse cardiac events during acute heart failure hospitalizations

Rani Paramitha Iswari Maliawan; I Ketut Badjra Nadha; I Gde Raka Widiana; I Gusti Ngurah Putra Gunadhi; Ida Sri Iswari; I Wayan Wita

doi:10.15562/bmj.v10i2.2541

Serum neutrophil gelatinase-associated lipocalin and decreased kidney function as predictor of mortality and major adverse cardiac events during acute heart failure hospitalizations

Rani Paramitha Iswari Maliawan ,

I Ketut Badjra Nadha ,

I Gde Raka Widiana ,

I Gusti Ngurah Putra Gunadhi ,

Ida Sri Iswari ,

I Wayan Wita ,

PDF |
DOI: https://doi.org/10.15562/bmj.v10i2.2541 |
Published: 2021-07-01

Abstract

Introduction: Decreased renal function is associated with a poor prognosis in acute heart failure (AHF). The current standard for assessing the decline in kidney function, creatinine, has several limitations. Serum Neutrophil gelatinase-associated lipocalin (NGAL) is one of the predictive biomarkers that was shown better at indicating an early AKI. Although several studies have examining the role of NGAL as a predictor for poor prognosis in various medical conditions, the result in AHF condition is still inconsistent. This study aimed to determine the role of serum NGAL and decreased renal function (estimated using serum creatinine) in predicting the mortality and major adverse cardiovascular (MACE) events during hospitalization in acute heart failure patients

Methods: Prospective cohort study with consecutive sampling was conducted in AHF patients who were treated at Sanglah General Hospital from July to September 2017. Serum NGAL and creatinine levels were measured at the onset of hospital admission and observed for mortality and MACE during hospitalization.

Results: Seventy-seven patients were involved in this study. We found hazard ratio (HR) serum NGAL to mortality was 7.8 (p = 0.009) and increased to 18,9 in multivariate analysis with cox proportional hazards regression model (p = 0.002). There were significant differences in survival (p = 0.002) between patients with high serum NGAL (424 hours survival rate, 95% CI 296-552) than low serum NGAL (baseline survival 680 hours; 95% CI 584-775) after log rank test. Meanwhile, the effect of serum NGAL on MACE and decreased of kidney function on mortality or MACE did not yield significant result.

Conclusion: High serum NGAL is an independent predictor of in-hospital mortality among AHF patients.

References

Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595-605.
Chan YK, Sung HK, Sweeney G. Iron metabolism and regulation by neutrophil gelatinase-associated lipocalin in cardiomyopathy. Clin Sci (Lond). 2015;129(10):851-862.
Helanova K, Littnerova S, Kubena P, et al. Prognostic impact of neutrophil gelatinase-associated lipocalin and B-type natriuretic in patients with ST-elevation myocardial infarction treated by primary PCI: a prospective observational cohort study. BMJ Open. 2015;5(10):e006872.
Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16(1):49-54.
Cruz DN, Fard A, Clementi A, Ronco C, Maisel A. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. Semin Nephrol. 2012;32(1):79-92.
De Berardinis B, Gaggin HK, Magrini L, et al. Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. Clin Chem Lab Med. 2015;53(4):613-621.
Soylu K, Aksan G, Nar G, et al. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol J Cardiol. 2015;15(6):450-455.
Lindberg S, Jensen JS, Hoffmann S, et al. Plasma Neutrophil Gelatinase-Associated Lipocalin Reflects Both Inflammation and Kidney Function in Patients with Myocardial Infarction. Cardiorenal Med. 2016;6(3):180-190.
van Deursen VM, Damman K, Voors AA, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail. 2014;7(1):35-42.
Alvelos M, Lourenço P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. International Journal of Cardiology. 2013;165(1):51-55.
Kang SM, Cho MC. Prognostic Factors in Hospitalization for Heart Failure in Asia. Heart Fail Clin. 2015;11(4):543-550.
Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European Journal of Heart Failure. 2011;13(8):846-851.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
Farmakis D, Parissis J, Lekakis J, Filippatos G. Acute heart failure: Epidemiology, risk factors, and prevention. Rev Esp Cardiol (Engl Ed). 2015;68(3):245-248.
Ito M, Doi K, Takahashi M, et al. Plasma neutrophil gelatinase-associated lipocalin predicts major adverse cardiovascular events after cardiac care unit discharge. J Cardiol. 2016;67(2):184-191.
Lahiri A, Alex AG, George PV. Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin (NGAL) level in patients with acute coronary syndromes (ACS), and its association with outcomes. Indian Heart Journal. 2017.
Elsharawy S, Raslan L, Morsy S, Hassan B, Khalifa N. Plasma neutrophil gelatinase-associated lipocalin as a marker for the prediction of worsening renal function in children hospitalized for acute heart failure. Saudi J Kidney Dis Transpl. 2016;27(1):49-54.
Breidthardt T, Socrates T, Drexler B, et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Critical Care. 2012;16(1):R2.
Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects. Critical Care. 2016;20(1).
Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8-14.
Sharifipour F, Hami M, Naghibi M, Zeraati A, Arian S, Azarian AA. RIFLE criteria for acute kidney injury in the intensive care units. J Res Med Sci. 2013;18(5):435-437.